Levepsy Syrup contains Levetiracetam 100 mg/ml, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. This syrup formulation is particularly suitable for pediatric patients or individuals who have difficulty swallowing tablets. Levepsy Syrup should be administered orally, with dosing individualized based on patient age, weight, and clinical response, typically starting at a low dose and gradually titrated to minimize adverse effects. Common side effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation. It is essential to monitor patients for mood alterations or suicidal ideation during therapy. Levepsy Syrup is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients. Caution is advised in patients with renal impairment, as dosage adjustment may be necessary. Levetiracetam does not induce hepatic enzymes and has a low potential for drug interactions, making it a favorable option in polytherapy. Always consult a healthcare professional before initiating or discontinuing treatment with Levepsy Syrup.